BTG2 and prostate carcinoma: To further explore the roles of TSPX in non-tumor prostate and the dosage dependent effects of TSPX in prostate cancer, the expression levels of tumor suppressors, SEMA3B and BTG2, and caner-drivers/oncogenes, MYC, MYB and AR, were compared among non-tumor prostate, TSPX-low prostate cancer, TSPX-mid prostate cancer, and TSPX-high prostate cancer samples.